Oncotarget

Research Papers:

A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector

Zhi Hong Lu, Sergey Kaliberov, Rebecca E. Sohn, Lyudmila Kaliberova, Yingqiu Du, Julie L. Prior, Daniel J. Leib, Anne Chauchereau, Jennifer K. Sehn, David T. Curiel and Jeffrey M. Arbeit _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:12272-12289. https://doi.org/10.18632/oncotarget.14699

Metrics: PDF 2168 views  |   HTML 3697 views  |   ?  


Abstract

Zhi Hong Lu1,2, Sergey Kaliberov2,3,4, Rebecca E. Sohn1,2, Lyudmila Kaliberova2,3,4, Yingqiu Du1,2, Julie L. Prior5, Daniel J. Leib6, Anne Chauchereau7, Jennifer K. Sehn2,8, David T. Curiel2,3,4, Jeffrey M. Arbeit1,2

1Urology Division and Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA

2Siteman Cancer Center, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA

3Biologic Therapeutics Center, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA

4Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA

5Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA

6Department of Orthopedic Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA

7Prostate Cancer Group, INSERM U981, Gustave Roussy, Villejuif, F-94805, France

8Department of Anatomic and Molecular Pathology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA

Correspondence to:

Jeffrey M. Arbeit, email: [email protected]

David T. Curiel, email: [email protected]

Keywords: prostate, metastasis, endothelial, niche, adenovirus

Received: August 12, 2016    Accepted: December 26, 2016    Published: January 17, 2017

ABSTRACT

While modern therapies for metastatic prostate cancer (PCa) have improved survival they are associated with an increasingly prevalent entity, aggressive variant PCa (AVPCa), lacking androgen receptor (AR) expression, enriched for cancer stem cells (CSCs), and evidencing epithelial-mesenchymal plasticity with a varying extent of neuroendocrine transdifferentiation. Parallel work revealed that endothelial cells (ECs) create a perivascular CSC niche mediated by juxtacrine and membrane tethered signaling. There is increasing interest in pharmacological metastatic niche targeting, however, targeted access has been impossible. Here, we discovered that the Gleason 7 derived, androgen receptor negative, IGR-CaP1 cell line possessed some but not all of the molecular features of AVPCa. Intracardiac injection into NOD/SCID/IL2Rg -/- (NSG) mice produced a completely penetrant bone, liver, adrenal, and brain metastatic phenotype; noninvasively and histologically detectable at 2 weeks, and necessitating sacrifice 4-5 weeks post injection. Bone metastases were osteoblastic, and osteolytic. IGR-CaP1 cells expressed the neuroendocrine marker synaptophysin, near equivalent levels of vimentin and e-cadherin, all of the EMT transcription factors, and activation of NOTCH and WNT pathways. In parallel, we created a new triple-targeted adenoviral vector containing a fiber knob RGD peptide, a hexon mutation, and an EC specific ROBO4 promoter (Ad.RGD.H5/3.ROBO4). This vector was expressed in metastatic microvessels tightly juxtaposed to IGR-CaP1 cells in bone and visceral niches. Thus, the combination of IGR-CaP1 cells and NSG mice produces a completely penetrant metastatic PCa model emulating end-stage human disease. In addition, the metastatic niche access provided by our novel Ad vector could be therapeutically leveraged for future disease control or cure.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14699